3811 - 3820 of 9034 Results
Title
Year
-
OPENTitle: CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s diseaseJournal Name: Acta NeuropathologicaPublisher: Springer Science and Business Media LLCVol: 126Issue #: 5Start Page: 683End Page: 697Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s00401-013-1148-zBest OA location URL: http://doi.org/10.1007/s00401-013-1148-zCitation Count: 112
-
OPENTitle: CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative studyJournal Name: Acta NeuropathologicaPublisher: Springer Science and Business Media LLCVol: 131Issue #: 6Start Page: 935End Page: 949Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s00401-016-1552-2Best OA location URL: https://resolver.sub.uni-goettingen.de/purl?gro-2/40503Citation Count: 219
-
OPENTitle: Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)Journal Name: Journal of NeurologyPublisher: Springer Science and Business Media LLCVol: 266Issue #: 5Start Page: 1203End Page: 1210Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s00415-019-09250-yBest OA location URL: https://link.springer.com/content/pdf/10.1007/s00415-019-09250-y.pdfCitation Count: 23
-
OPENTitle: Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohortJournal Name: Journal of NeurologyPublisher: Springer Science and Business Media LLCVol: 266Issue #: 8Start Page: 1927End Page: 1936Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s00415-019-09348-3Best OA location URL: https://link.springer.com/content/pdf/10.1007/s00415-019-09348-3.pdfCitation Count: 232
-
OPENTitle: Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changesJournal Name: Journal of NeurologyPublisher: Springer Science and Business Media LLCVol: 268Issue #: 1Start Page: 337End Page: 345Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s00415-020-10163-4Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/7855683Citation Count: 18
-
OPENTitle: Disentangling the PIGD classification for the prediction of cognitive impairment in de novo Parkinson’s diseaseJournal Name: Journal of NeurologyPublisher: Springer Science and Business Media LLCVol: 269Issue #: 3Start Page: 1566End Page: 1573Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s00415-021-10730-3Best OA location URL: https://link.springer.com/content/pdf/10.1007/s00415-021-10730-3.pdfCitation Count: 14
-
OPENTitle: An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 CohortsJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 10Issue #: 2Start Page: 623End Page: 629Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-191786Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd191786?id=journal-of-parkinsons-disease%2Fjpd191786Citation Count: 49
-
OPENTitle: Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 12Issue #: 2Start Page: 557End Page: 570Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-212714Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd212714?id=journal-of-parkinsons-disease%2Fjpd212714Citation Count: 60
-
OPENTitle: Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 TrialsJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 11Issue #: 4Start Page: 1663End Page: 1675Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-212672Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd212672?id=journal-of-parkinsons-disease%2Fjpd212672Citation Count: 39
-
OPENTitle: Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 UpdateJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 13Issue #: 4Start Page: 427End Page: 439Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-239901Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd239901?id=journal-of-parkinsons-disease%2Fjpd239901Citation Count: 89